August 8, 2022
Fat and Happy
Is it possible that the fight against fat will not only transform the diabetes drug market but also change the dynamics of the CGM market? It’s not only possible this change is already underway. Right this very moment Lilly and Novo Nordisk are battling for supremacy in the excuse the expression expanding obesity market. Both offer simple and very effective solutions which were originally intended for patients with Type 2 diabetes.
Yet as effective as these therapies are there are patients who prefer not to use medications to lose weight and would rather transform their habits. A whole crop . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.
